<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-09-11">11 September 2014.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">T</forename><surname>Schwarz</surname></persName>
							<email>t.schwarz@juliusspital.de</email>
							<affiliation key="aff0">
								<orgName type="laboratory">Central Laboratory and Vaccination Centre</orgName>
								<orgName type="institution">Stiftung Juliusspital</orgName>
								<address>
									<addrLine>W€ urzburg</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Gynecology, and Obstetrics</orgName>
								<orgName type="institution">University of Sao Paulo Medical School</orgName>
								<address>
									<settlement>Sao Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Spaczynski</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Poznan University of Medical Sciences</orgName>
								<address>
									<addrLine>Pozna n</addrLine>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Obstetrics and Gynecology Weill Cornell Medical College</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Kaufmann</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Charit e Universit€ atsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Wysocki</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Preventive Medicine</orgName>
								<orgName type="institution">University School of Medical Sciences</orgName>
								<address>
									<addrLine>Pozna n</addrLine>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Gałaj</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Vitamed Bydgoszcz</orgName>
								<address>
									<settlement>Bydgoszcz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Schulze</surname></persName>
							<affiliation key="aff5">
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Suryakiran</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">GlaxoSmithKline Vaccines</orgName>
								<address>
									<settlement>Bangalore</settlement>
									<country key="IN">India</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Thomas</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">GlaxoSmithKline Vaccines</orgName>
								<address>
									<settlement>Wavre</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Descamps</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">GlaxoSmithKline Vaccines</orgName>
								<address>
									<settlement>Wavre</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Linhares</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Central Laboratory and Vaccination Centre</orgName>
								<orgName type="institution">Stiftung Juliusspital</orgName>
								<address>
									<addrLine>W€ urzburg</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Gynecology, and Obstetrics</orgName>
								<orgName type="institution">University of Sao Paulo Medical School</orgName>
								<address>
									<settlement>Sao Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Witkin</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Gynecologic Oncology</orgName>
								<orgName type="institution">Poznan University of Medical Sciences</orgName>
								<address>
									<addrLine>Pozna n</addrLine>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Obstetrics and Gynecology Weill Cornell Medical College</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="laboratory">Central Laboratory and Vaccination Centre</orgName>
								<orgName type="institution">Stiftung Juliusspital W€ urzburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-09-11">11 September 2014.</date>
						</imprint>
					</monogr>
					<idno type="MD5">8460572F3F196870A5F20D793B0B748C</idno>
					<idno type="DOI">10.1111/1471-0528.13069.</idno>
					<note type="submission">Accepted 6 July 2014.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:50+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Design Multicentre, open-label, long-term follow-up (NCT00947115) of a primary phase-III study (NCT00196937).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>]<ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref> In Europe, cervical cancer is the second most frequent cancer among women aged 15-44 years. <ref type="bibr" target="#b7">8</ref></s><s>e copyright line for this article was changed on 6 January 2015 after original online publication.</s></p><p><s>Approximately 10% of women worldwide with a normal cervical cytology carry a detectable cervical HPV infection. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref></s><s>]<ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> About 100 million women worldwide carry HPV-16/18 DNA, and the detection of HPV-16/18 is associated with a five-fold greater risk of developing CIN than the detection of other HR HPV types. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b18">19</ref></s><s>1]<ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> Therefore, in addition to the current vaccination programmes targeting adolescent girls before their sexual debut, vaccination of women aged &gt;25 years should be considered on an individual basis. <ref type="bibr" target="#b25">26</ref></s><s>2]<ref type="bibr" target="#b34">[33]</ref><ref type="bibr" target="#b35">[34]</ref><ref type="bibr" target="#b36">[35]</ref><ref type="bibr" target="#b37">[36]</ref><ref type="bibr" target="#b39">[37]</ref> Recently, a high vaccine efficacy has also been demonstrated in women aged ≥26 years. <ref type="bibr" target="#b40">38</ref></s><s>The vaccine was also shown to have a clinically acceptable safety profile. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b41">39</ref></s><s>In Europe, it is indicated for use in girls from 9 years of age. <ref type="bibr" target="#b42">40</ref></s><s>n a previously published primary open-label phase-III study, the HPV-16/18 AS04-adjuvanted vaccine was immunogenic and well tolerated in women aged 15-55 years; in addition, a high correlation between anti-HPV-16/18 antibody levels in sera and cervicovaginal secretion (CVS) samples was observed, regardless of age. <ref type="bibr" target="#b43">41</ref></s><s>In the first follow-up of the primary study (NCT00196937), immune responses to the vaccine were sustained up to 2 years after vaccination; CVS anti-HPV-16/18 antibodies were not assessed. <ref type="bibr" target="#b30">30</ref></s><s>he current extended follow-up evaluates the long-term persistence of antibody responses, up to 10 years after the first dose, in women vaccinated in the primary study.</s><s>Here, we report persistence of the serum and CVS anti-HPV-16/ 18 antibodies, and vaccine safety, up to 6 years after vaccination.</s><s>In addition, we present for the first time modelling data predicting long-term anti-HPV-16/18 antibody persistence in vaccinated women aged &gt;25 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>This study is a multicentre, open-label, age-stratified, longterm follow-up (LTFU) of the primary study (NCT00196937), conducted in six centres in Poland and Germany between October 2004 and July 2005, in which healthy women aged 15-55 years, stratified in three age groups (15-25, 26-45, and 46-55 years), received three doses of the HPV-16/18 AS04-adjuvanted vaccine at 0, 1, and 6 months.</s><s>The immunogenicity persistence and vaccine safety will be evaluated up to 10 years after the first dose.</s><s>Here, we present the results obtained up to 6 years after the first dose.</s><s>The overall study design is summarised in Figure <ref type="figure" target="#fig_0">1</ref>.</s></p><p><s>All women participating in the study provided written informed consent prior to enrolment.</s><s>This study was conducted in accordance with the Good Clinical Practice guidelines and all applicable regulatory requirements, including the Declaration of Helsinki.</s><s>This study has been registered at www.clinicaltrials.gov</s><s>(NCT00947115).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study objectives</head><p><s>The primary study objective was to evaluate the long-term immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in terms of anti-HPV-16 and anti-HPV-18 geometric mean antibody titres (GMTs) and seroconversion rates in serum, measured by enzyme-linked immunosorbent assay (ELISA) 6 years after the first dose.</s></p><p><s>Extended follow-up study (NCT00196937). <ref type="bibr" target="#b30">30</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study vaccine</head><p><s>Each dose of the HPV-16/18 AS04-adjuvanted vaccine contained 20 lg each of HPV-16 and HPV-18 L1 virus-like particles (VLPs) formulated with the AS04 adjuvant system, comprising 50 lg 3-O-desacyl-4 0 -monophosphoryl lipid A and 500 lg Al(OH) 3 .</s><s>The vaccine was supplied in individual 0.5-ml pre-filled syringes and administered into the deltoid muscle.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>Only women who completed the full vaccination course in the primary study were eligible for inclusion in this extended LTFU study.</s><s>Inclusion and exclusion criteria for the primary study were previously described. <ref type="bibr" target="#b43">41</ref></s><s>munogenicity assessment</s></p><p><s>Blood samples for immunogenicity assessment were collected at 0, 2, 7, 12, 18, 24, 36, 48, 60 (year 5), and 72 months (year 6), and CVS samples (from women who volunteered) were collected at 18, 24, 60, and 72 months, as previously described. <ref type="bibr" target="#b43">41</ref></s><s>In this LTFU study, we assessed samples collected at year 5 and year 6 (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Anti-HPV-16 and anti-HPV-18 antibody titres in serum and CVS samples were measured by ELISA using type-specific VLPs as coating antigens (serum standardised protocol). <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b33">32,</ref><ref type="bibr" target="#b34">33,</ref><ref type="bibr" target="#b43">41,</ref><ref type="bibr" target="#b45">42</ref></s><s>Total immunoglobulin G (IgG) levels were measured to account for variation during the menstrual cycle.</s><s>IgG titres were evaluated in both serum and CVS samples to standardise the immunogenicity results by dividing each anti-HPV-16 and anti-HPV-18 titre by the corresponding total IgG titre.</s><s>Seropositivity was defined as antibody titres ≥ 8 ELISA units (EU)/ml or ≥ 7 EU/ml for anti-HPV-16 and anti-HPV-18, respectively. <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b43">41</ref></s><s>Anti-HPV-16/18 GMTs resulting from natural infection used in this study were previously determined in women aged 15-25 years. <ref type="bibr" target="#b36">35</ref></s><s>ediction of long-term persistence of anti-HPV-16/18 antibody responses Modelling of the long-term persistence of anti-HPV-16/18 antibody responses was assessed as described previously. <ref type="bibr" target="#b46">43</ref></s><s>riefly, two mixed-effects statistical models, the modified power-law model and the piecewise model, were fitted to the individual anti-HPV-16/18 titres measured at each time point up to year 6 in women vaccinated with the HPV-16/ 18 AS04-adjuvanted vaccine in the primary study, and for whom post-vaccination results were available.</s><s>To estimate post-vaccination antibody decay over time, the modified power-law model includes B-cell dynamics, in which two B-cell populations (activated and memory B-cells) are involved, accounting for the long-term persistence of a memory B-cell subpopulation and a long-term antibody plateau.</s><s>The piecewise model fits the data on three non-overlapping time intervals, corresponding to the observed decay of humoral antibodies.</s><s>Each piece of the model used a linear function; three break points (7, 12, and 21 months) were selected.</s><s>The two model effects were fitted using an NLMIXED SAS procedure.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety assessment</head><p><s>Although no study vaccine was administered in this LTFU study, all serious adverse events (SAEs) related to vaccination, study participation, or concomitant GlaxoSmithKline Vaccines medication were recorded during the entire study period.</s></p><p><s>All women with SAEs or who were withdrawn from the study because of SAEs were followed until the SAE had resolved, subsided, stabilised, disappeared, or been otherwise explained.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>All analyses were performed using SAS 9.2 and PROC STAT-XACT 8.1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study cohorts</head><p><s>The primary cohort for analysis of blood sample results at year 6 was the according-to-protocol (ATP) cohort for immunogenicity, which comprised all women included in the ATP immunogenicity analysis in the primary study, meeting all eligibility criteria, complying with procedures defined in the protocol, with no elimination criteria during the study, who attended the year-6 visit, and for whom serology results at year 6 were available.</s></p><p><s>The primary cohort for analysis of CVS sample results at year 6 was the total vaccinated cohort (TVC), comprising all women who volunteered for CVS sampling at year 6 and for whom CVS results were available at this time point.</s></p><p><s>The year-6 TVC for safety included all women participating in the current LTFU study.</s><s>Two safety analyses were performed.</s><s>The first was based on TVC data collected during this LTFU study from the last visit of the previous follow-up study (up to month 48) to the last visit in this follow-up study (year 6); the second analysis was based on the TVC data collected for the entire study period (from month 0 to year 6).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity analyses</head><p><s>Immunogenicity analyses were age-stratified (15-25, 26-45,  and 46-55 years at first vaccination).</s></p><p><s>Seroconversion was defined as the appearance of antibodies, with titres greater than or equal to the cut-off values, in sera of women who were seronegative before vaccination in the primary study.</s><s>Conversion for CVS analyses was defined as the appearance of antibodies, with titres greater than or equal to the limits of quantifi-cation, in CVS samples of women who tested negative before vaccination in the primary study.</s><s>Seropositivity rates and anti-HPV-16/18 GMTs were calculated with exact 95% confidence intervals (95% CIs).</s><s>GMT calculations were performed by taking the antilog of the mean of the log titre transformations.</s><s>In the absence of an accepted serological correlate of protection, we performed descriptive comparisons with anti-HPV-16/18 serology results from a previous efficacy study, <ref type="bibr" target="#b33">32,</ref><ref type="bibr" target="#b34">33</ref> and with anti-HPV-16/18 titres achieved after natural infection in another study. <ref type="bibr" target="#b36">35,</ref><ref type="bibr" target="#b37">36</ref></s><s>fety analyses Safety analyses were age-stratified (15-25, 26-45, and 46-55 years).</s><s>Vaccine-, study participation-or concomitant GlaxoSmithKline Vaccines medication-related SAEs and fatal SAEs were described in detail.</s><s>Vaccine-related SAEs were further evaluated for clinical relevance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p><s>In the primary study, 666 women received at least one dose of the HPV-16/18 AS04-adjuvanted vaccine.</s><s>Of the 647 women who received three vaccine doses in the primary study, 159 did not show up for the follow-up visit after 6 years.</s><s>At year 6, the TVC comprised 488 women, of whom 477 were included in the ATP cohort for immunogenicity (Figure <ref type="figure" target="#fig_2">2</ref>).</s><s>Most women (99.8%) were white/ caucasian.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p><s>Serological immune response Of the 644 women included in the ATP immunogenicity cohort in the primary study at baseline, over 70% were seronegative for both anti-HPV-16 and anti-HPV-18; among women in the age groups 15-25, 26-45, and 46-55 years, 82.5, 67.4, and 66.3% were seronegative for both HPV-16 and HPV-18, respectively, and only 6% (2.7, 6.9, and 9.0% in the age groups 15-25, 26-45, and 46-55 years, respectively) were seropositive for both HPV-16 and HPV-18. <ref type="bibr" target="#b43">41</ref></s><s>One month following the third vaccine dose (month 7), all initially seronegative women were seropositive for anti-HPV-16/18 antibodies. <ref type="bibr" target="#b43">41</ref></s><s>t year 6, all women remained seropositive for anti-HPV-16 antibodies and at least 97% were seropositive for anti-HPV-18 antibodies.</s><s>Four women who were initially seronegative for anti-HPV-18 were still seronegative at year 6 (age group 46-55 years).</s></p><p><s>Antibody kinetics for both anti-HPV-16 and anti-HPV-18 showed a peak in antibody levels at month 7, followed by a gradual decline until month 18. <ref type="bibr" target="#b36">35,</ref><ref type="bibr" target="#b37">36</ref> This decline became less pronounced over time, suggesting that a plateau phase had been reached (Figure <ref type="figure" target="#fig_3">3</ref>).</s><s>An age-dependent decrease in GMTs observed at the previous time points was also observed at year 6, as indicated by non-overlapping 95% CIs between the age groups (Figure <ref type="figure" target="#fig_3">3</ref>).</s></p><p><s>At year 6, in initially seronegative women, anti-HPV-16 GMTs were 1344.6 EU/ml (95% CI 1130.2-1599.6</s><s>EU/ml), 526.0 EU/ml (95% CI 434.7-636.4</s><s>EU/ml), and 277.7 EU/    <ref type="bibr" target="#b36">35,</ref><ref type="bibr" target="#b37">36</ref> Plateau: GMTs of women aged 15-25 years at months 45-50 after the first vaccine dose (total vaccinated cohort).</s><s>GMTs were (A) 397.8 EU/ml and (B) 297.3 EU/ml. <ref type="bibr" target="#b34">33</ref></s><s>The error bars represent 95% confidence intervals.</s><s>groups, respectively.</s><s>CVS anti-HPV-16 GMTs were 80.3, 43.8, and 37.1 EU/ml in the age groups 15-25, 26-45, and 46-55 years, respectively, and anti-HPV-18 GMTs were 22.9, 19.9, and 19.2 EU/ml.</s></p><p><s>At year 6, women with detectable anti-HPV-16/18 antibodies in their CVS samples had higher serum anti-HPV-16/18 GMTs than women with no antibodies detected in their CVS samples: for anti-HPV-16 they were between two-and five-fold higher and for anti-HPV-18 they were between one-and five-fold higher, depending on the age group (data not shown).</s></p><p><s>To account for the fluctuation in total IgG levels observed during the menstrual cycle, anti-HPV-16/18 antibody levels were standardised relative to the total IgG levels before evaluating the correlation.</s><s>Correlations between the serum and CVS titres (standardised for total IgG) in the three age groups at year 6 are presented in Figure <ref type="figure" target="#fig_5">4</ref>.</s><s>For anti-HPV-16, the correlation coefficients were high regardless of age, and ranged from 0.87 to 0.91 at year 5, <ref type="bibr" target="#b47">44</ref> and from 0.81 to 0.96 at year 6 (Figure <ref type="figure" target="#fig_5">4A</ref>); for anti-HPV-18, they ranged from 0.84 to 0.87 at year 5, <ref type="bibr" target="#b47">44</ref> and from 0.69 to 0.84 at year 6 (Figure <ref type="figure" target="#fig_5">4B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Predicted long-term persistence of antibody responses</head><p><s>The long-term persistence of anti-HPV-16/18 antibody responses was predicted for the three age groups using the modified power-law and piecewise models, based on the 6-year immunogenicity data from the current study.</s><s>Immunogenicity data obtained at 6.4 years after vaccination in a previous study in women aged 15-25 years were also included in the models (Figure <ref type="figure">5</ref>). <ref type="bibr" target="#b28">28</ref></s><s>The modified powerlaw model predicted that mean anti-HPV-16/18 levels would remain above those associated with natural infection for at least 20 years in all age groups.</s><s>The piecewise model predicted that anti-HPV-16 GMTs would remain above GMTs associated with natural infection for all age groups, whereas anti-HPV-18 GMTs would remain above the natural infection levels for the age groups 15-25 and 26-45 years, but not for the age group 46-55 years (Table <ref type="table" target="#tab_1">1</ref>).</s><s>Additional modelbased estimations were performed to predict the duration ensuring that 95% of women would have anti-HPV-16/18 levels remaining above the natural infection level.</s><s>The modified power-law model predicted lifelong anti-HPV-16 levels above the natural infection level for all women, and lifelong anti-HPV-18 levels above the natural infection level in the age groups 15-25 and 26-45 years; for the age group 46-55 years, the modified power-law model predicted that 95% of women would still have anti-HPV-18 levels above natural infection levels after 4.3 years.</s><s>The piecewise model predicted durations of antibody levels remaining above natural infection levels of up to 40.1, 16.9, and 12.1 years for anti-HPV-16, and up to 19.2, 9.0, and 5.1 years for anti-HPV-18 for 95% of women in the age groups 15-25, 26-45, and 46-55 years, respectively (Table <ref type="table">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The HPV-16/18 AS04-adjuvanted vaccine had a clinically acceptable safety profile in all age groups throughout the entire study duration.</s><s>Twenty-eight women reported 32 SAEs.</s><s>One woman (in the age group 26-45 years) reported one SAE (optic neuritis), considered by the investigators as causally related to the study vaccination; as a result of this SAE, the vaccination course of the women was discontinued, but she was not withdrawn from the study.</s><s>This SAE occurred during the primary study and was resolved therein, as previously reported. <ref type="bibr" target="#b43">41</ref></s><s>Two fatal SAEs occurred during the entire study period: one woman committed suicide and one had a road accident.</s><s>Both of these SAEs were reported in the age group 46-55 years, and both were considered unrelated to the vaccination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Main findings</head><p><s>Immune responses to the HPV-16/18 AS04-adjuvanted vaccine persisted up to 6 years after vaccination in women aged 15-55 years.</s><s>At year 6, all women remained seropositive for anti-HPV-16 and ≥97% were seropositive for anti-HPV-18 antibodies, with anti-HPV-16/18 GMTs higher than levels associated with natural infection; anti-HPV-16 and anti-HPV-18 antibodies were detected  in about 72 and 53.8-69.0% of CVS samples, respectively.</s><s>A strong correlation between serum and CVS anti-HPV-16/18 GMTs was observed; serum anti-HPV-16/ 18 GMTs were higher in women with detectable CVS anti-HPV-16/18 antibodies.</s><s>Exploratory modelling based on the 6-year data predicted that vaccine-induced population anti-HPV-16/18 GMTs would remain above those associated with natural infection for at least 20 years after vaccination.</s><s>The vaccine had a clinically acceptable safety profile.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strengths and weaknesses</head><p><s>This study included both young and mature women, allowing for a comparison of anti-HPV-16/18 levels between age groups.</s><s>Although a sustained HPV-16/18 AS04-adjuvanted vaccine immunogenicity has been reported in women aged 15-25 years, <ref type="bibr" target="#b35">34,</ref><ref type="bibr" target="#b39">37</ref> to our knowledge this is the first study reporting such long-term (up to 6 years post-vaccination) persistence of antibody responses and correlation of the serum and CVS anti-HPV-16/18 antibodies in women aged &gt;25 years.</s><s>Using statistical models, we could for the first time predict the persistence of anti-HPV-16/18 responses for up to 20 years in mature women.</s><s>The main study limitations include open design, the lack of a direct control group, and antibody assessment only by ELISA.</s><s>Assessment of neutralising antibodies, avidity, and cell-mediated immune responses for vaccine and non-vaccine HPV types would provide added value.</s><s>Another limitation might be the lack of cervical screening data, which could help determine a clinical correlation with the immune data; however, the current study was designed to evaluate the HPV-16/18 AS04-adjuvanted vaccine immunogenicity and safety, and not its efficacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interpretation</head><p><s>We previously showed that the HPV-16/18 AS04-adjuvanted vaccine was immunogenic in women aged 15-55 years for up to 48 months. <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b43">41</ref></s><s>Here, we report the immunogenicity persistence up to 6 years after vaccination.</s><s>Anti-HPV-16/18 antibody kinetics were similar in all age groups and similar to those reported previously, with a peak response at month 7, followed by a gradual decline. <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b34">33,</ref><ref type="bibr" target="#b43">41,</ref><ref type="bibr" target="#b48">45</ref></s><s>The highest anti-HPV-16/18 levels were observed in the age group 15-25 years, in line with previous observations, <ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b43">41</ref> and consistent with findings that immune responses decline with increasing age. <ref type="bibr" target="#b49">46</ref></s><s>lthough an immunological correlate of protection has not yet been identified, high and sustained antibody titres obtained through vaccination are considered predictive of long-term protection against oncogenic HPV infections and CIN. <ref type="bibr" target="#b50">47,</ref><ref type="bibr" target="#b51">48</ref></s><s>We compared anti-HPV-16/18 levels with GMT plateaus associated with sustained protection at months 45-50 in a previous study on efficacy. <ref type="bibr" target="#b34">33</ref></s><s>In our study, anti-HPV-16/18 levels at year 6 remained above the predefined plateau levels of sustained efficacy in the age group 15-25 years, <ref type="bibr" target="#b34">33</ref> and in all age groups the levels were substantially higher than the natural infection levels. <ref type="bibr" target="#b36">35</ref></s><s> previous modelling study showed the persistence of anti-HPV-16/18 antibody responses up to 20 years following vaccination with the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-25 years.</s><s><ref type="bibr" target="#b46">43</ref> We report for the first time the modelling of antibody responses of up to 20 years after vaccination in older women.</s><s>Based on our 6-year immunogenicity data, the modified power-law model predicted that post-vaccination anti-HPV-16/18 GMTs would remain substantially higher than levels associated with natural infection for at least 20 years in women aged 15-Table <ref type="table">2</ref>. Predicted duration ensuring that 95% of women would still have anti-HPV-16 and anti-HPV-18 antibody levels above natural infection levels in women aged 15-25, 26-45, and 46-55  55 years.</s><s>Anti-HPV-16/18 GMTs predicted using the more conservative piecewise model were lower than those predicted with the modified power-law model, but were higher than natural infection levels, except for the age group 46-55 years.</s><s>Based on immunogenicity data from a previous study (HPV-001), <ref type="bibr" target="#b28">28</ref> or from the current study for the age groups 15-25 years, both models predicted similar anti-HPV-18 GMTs and lower anti-HPV-16 GMTs 20 years after vaccination.</s><s>These different predictions may result from the different pre-established assumptions for each model.</s><s>The modified power-law model is based on the assumption that B-cell memory does not decline over time, whereas the piece-wise model assumes that antibody responses follow a linear decrease over time, and takes into account only antibody levels obtained in a given study.</s></p><p><s>Hence, the piecewise model is likely to yield a more conservative estimate of long-term protection. <ref type="bibr" target="#b46">43</ref></s><s>As the duration of protection associated with HPV vaccination is of crucial importance in cost-effectiveness, our modelling data could serve as a basis to assess the economic impact of cervical cancer vaccination programmes.</s><s>Finally, a high HPV-16/18 AS04-adjuvanted vaccine efficacy (81.1%, 97.7% CI 52.1-94.0%)</s><s>against HPV-16/18-related CIN1+ and 6-month persistent infection has been recently demonstrated in women aged ≥26 years. <ref type="bibr" target="#b40">38</ref></s><s>Altogether, these previous results and our immunogenicity data suggest that the HPV-16/18 AS04-adjuvanted vaccine provides a sustained protection against HPV-16/18 infection in women aged &gt;25 years.</s><s>A significant relationship between naturally acquired anti-HPV-16 antibodies and the risk of new infection has been reported: the incidence of infection declined with increasing antibody titres. <ref type="bibr" target="#b52">49</ref></s><s>In another study, unvaccinated women with higher anti-HPV-16/18 levels had significantly lower risk of subsequent HPV-16/18 infection than seronegative women, suggesting that natural infection confers a certain degree of protection against new HPV-16/18 infections. <ref type="bibr" target="#b53">50</ref></s><s>Antibody levels after natural infection are much lower than those generated through vaccination, however, and thus natural infection confers only partial protection.</s><s>The mechanism by which prophylactic HPV vaccines induce protection is assumed to be mediated by vaccine-induced neutralising IgG antibodies, which transudate across cervical epithelium to the HPV infection site and are likely to prevent HPV infection of the cervical basal cell layer at the transformation zone. <ref type="bibr" target="#b50">47,</ref><ref type="bibr" target="#b52">49,</ref><ref type="bibr" target="#b54">51,</ref><ref type="bibr" target="#b55">52</ref></s><s>We observed a strong correlation between the serum and CVS anti-HPV-16/18 levels that persisted up to 6 years after vaccination.</s><s>To our knowledge, this is the first study showing such long persistence of anti-HPV-16/18 antibody transudation following vaccination with HPV-16/18 AS04-adjuvanted vaccine in women aged &gt;25 years.</s><s>Although anti-HPV-16/18 levels in serum decreased since the first assessment time point (month 24) in the primary study, <ref type="bibr" target="#b43">41</ref> correlation between the serum and CVS antibody levels at year 6 remained high in all age groups.</s><s>A pooled analysis of data from four clinical trials assessing serum and CVS anti-HPV-16/18 correlation following administration of the HPV-16/18 AS04-adjuvanted vaccine has shown that higher antibody levels in serum resulted in higher antibody levels in CVS, supporting transudation of serum antibodies as the mechanism by which antibodies are introduced into CVS. <ref type="bibr" target="#b54">51</ref></s><s>Furthermore, in a phase-IV clinical trial in girls aged 12-15 years vaccinated with the HPV-16/ 18 AS04-adjuvanted vaccine, or Gardasil â , cross-neutralising antibodies were detected at the genital site of infection. <ref type="bibr" target="#b56">53</ref></s><s>he HPV-16/18 AS04-adjuvanted vaccine safety profile was consistent with that described in previous reports. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b32">31,</ref><ref type="bibr" target="#b37">36</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>The HPV-16/18 AS04-adjuvanted vaccine was well tolerated and induced sustained immune responses in women aged 15-55 years.</s><s>Anti-HPV-16/18 antibody levels remained several-fold higher than levels associated with natural infection for at least 6 years after vaccination.</s><s>Exploratory modelling of antibody persistence based on the 6-year data predicted that vaccine-induced anti-HPV-16/18 GMTs would remain above those induced by natural infection for at least 20 years, except for anti-HPV-18 levels in the age group 46-55 years (piecewise model).</s><s>A strong correlation between anti-HPV-16/18 levels in serum and CVS samples 6 years after vaccination indicates a long-lasting transudation of serum antibodies across the cervical epithelium.</s><s>These results suggest that in addition to the routine vaccination programmes in adolescents, sexually active mature women could potentially also benefit from vaccination with HPV-16/18 AS04-adjuvanted vaccine on an individual basis.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>Study design. 1 NCT00196937.41 2  Extended follow-up study (NCT00196937).30 3  Long-term follow-up study (current study) NCT00947115.</s><s>*Data presented here are for the year 6 (month 72) time point.</s></p></div></figDesc><graphic coords="2,130.39,561.70,315.00,107.36" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Figure1.</s><s>Study design. 1 NCT00196937.41 2  Extended follow-up study (NCT00196937).30 3  Long-term follow-up study (current study) NCT00947115.</s><s>*Data presented here are for the year 6 (month 72) time point.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Flow chart of study participants.</s><s>Key: 15-25 years, women aged 15-25 years at the time of first vaccine dose; 26-45 years, women aged 26-45 years at the time of first vaccine dose; 46-55 years, women aged 46-55 years at the time of first vaccine dose; ATP, according to protocol; N = total number of women; n = number of women in the age group; TVC, total vaccinated cohort.</s><s>*Participants may have more than one reason for exclusion.</s></p></div></figDesc><graphic coords="4,130.39,431.54,314.64,217.62" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure3.</s><s>Anti-HPV-16 (A) and anti-HPV-18 (B) antibody levels in initially seronegative women aged 15-55 years (ATP cohort for immunogenicity at year 6).</s><s>Key:[15-25], women aged 15-25 years at the time of first vaccine dose;[26-45], women aged 26-45 years at the time of first vaccine dose;[46-55], women aged 46-55 years at the time of first vaccine dose; GMT, geometric mean titre; Nat-inf, natural infection.</s><s>GMTs of women who were (A) HPV-16 or (B) HPV-18 DNA-negative and seropositive at baseline (i.e. who had cleared a natural infection).</s><s>GMTs were (A) 29.8 EU/ml and (B) 22.6 EU/ml.<ref type="bibr" target="#b36">35,</ref><ref type="bibr" target="#b37">36</ref></s><s>Plateau: GMTs of women aged 15-25 years at months 45-50 after the first vaccine dose (total vaccinated cohort).</s><s>GMTs were (A) 397.8 EU/ml and (B) 297.3 EU/ml.<ref type="bibr" target="#b34">33</ref></s><s>The error bars represent 95% confidence intervals.</s></p></div></figDesc><graphic coords="5,150.31,324.02,314.85,305.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Correlation of ratio between cervicovaginal secretion and serum samples by age for anti-HPV-16 (A) and anti-HPV-18 (B) antibody levels at year 6 in women aged 15-55 years (total vaccinated cohort).</s><s>Key: [15-25], women aged 15-25 years at the time of first vaccine dose; [26-45], women aged 26-45 years at the time of first vaccine dose; [46-55], women aged 46-55 years at the time of first vaccine dose; CVS, cervicovaginal secretion; R, correlation coefficient.</s><s>Titres were measured using an ELISA assay for the detection of anti-HPV-16 and anti-HPV-18 antibodies both for cervicovaginal secretion and serum samples.</s><s>The scatter plots show the ratio (specific IgG/total IgG) transformed to linear log10 values.</s></p></div></figDesc><graphic coords="6,50.77,495.53,476.31,143.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>4 12. 9 *Figure 5 .</head><label>95</label><figDesc><div><p><s>Figure 5. Prediction of antibody responses against HPV-16 and HPV-18 over 20 years using the modified power-law and the piecewise models in women aged 15-55 years (TVC at year 6).</s><s>(A) Anti-HPV-16 antibody levels prediction by the modified power-law model; (B) anti-HPV-18 antibody levels prediction by the modified power-law model; (C) anti-HPV-16 antibody levels prediction by modified piecewise model; (D) anti-HPV-18 antibody levels prediction by piecewise model.</s><s>Key: [15-25], women aged 15-25 years at the time of first vaccine dose; [26-45], women aged 26-45 years at the time of first vaccine dose; [46-55], women aged 46-55 years at the time of first vaccine dose; HPV-001 [15-25] 6.4Y-FU, anti-HPV-16 or anti-HPV-18 antibody levels at 6.4 years in women aged 15-25 years from a previous HPV-001 study;<ref type="bibr" target="#b28">28</ref> Nat-inf, natural infection: geometric mean titres (GMTs) of women who were HPV-16 or HPV-18 DNA-negative and seropositive at baseline (i.e. who had cleared a natural infection).</s><s>GMTs were 29.8 EU/ml for HPV-16 and 22.6 EU/ml for HPV-18.<ref type="bibr" target="#b36">35,</ref><ref type="bibr" target="#b37">36</ref></s></p></div></figDesc><graphic coords="7,88.42,65.24,438.88,296.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>33,365% CI 228.0-338.2EU/ml) in the age groups 15-25, 26-45, and 46-55 years, respectively.Anti-HPV-18 GMTs were 438.2 EU/ml (95% CI 366.6-523.7 EU/ml), 167.5 EU/ ml (95% CI 138.1-203.1 EU/ml), and 97.6 EU/ml (95% CI 79.2-120.3EU/ml) in these age groups, respectively.Anti-HPV-16/18 titres were higher than those achieved after natural infection in all age groups: for initially seronegative women, anti-HPV-16 GMTs were approximately 45.1-, 17.7-, and 9.3-fold higher in the age groups 15-25, 26-45, and 46-55 years, respectively, than the natural infection level (29.8 EU/ml).35Anti-HPV-18GMTswereapproximately19.4-, 7.4-, and 4.3-fold higher in these age groups, respectively, than the natural infection level (22.6 EU/ml).35,36Atyear6,anti-HPV-16GMTs</s><s>were 3.4-fold higher (in the age group 15-25 years) or remained within a similar range (in the age group 26-45 years) when compared with the plateau level established in a previous efficacy study at 45-50 months (397.8EU/ml).In the age group 15-25 years, anti-HPV-18 GMTs were also higher(1.5-fold)thantheGMT</s><s>plateau level observed in the previous efficacy study at 45-50 months (297.3EU/ml).33In</s><s>the age groups 26-45 and 46-55 years, anti-HPV-18 GMTs were lower than this predefined GMT plateau level (0.6-fold and 0.3-fold, respectively), with non-overlapping 95% CIs.</s></p></div></figDesc><table /><note><p><s>33In the age group 46-55 years, anti-HPV-16 GMTs were below the plateau level (0.7-fold; non-overlapping 95% CIs).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Predicted population GMTs for anti-HPV-16 and anti-HPV-18 at 20 years after the first vaccination in women aged 15-55 years</s></p></div></figDesc><table><row><cell>Antigen</cell><cell>Model</cell><cell cols="3">Predicted GMTs 20 years after the first vaccination (EU/ml)*</cell></row><row><cell></cell><cell></cell><cell>15-25 years**</cell><cell>26-45 years***</cell><cell>46-55 years****</cell></row><row><cell>HPV-16</cell><cell>Modified power-law</cell><cell>1092.3</cell><cell>404.2</cell><cell>272.4</cell></row><row><cell></cell><cell>Piecewise</cell><cell>474.9</cell><cell>127.1</cell><cell>67.8</cell></row><row><cell>HPV-18</cell><cell>Modified power-law</cell><cell>337.3</cell><cell>132.3</cell><cell>82.2</cell></row><row><cell></cell><cell>Piecewise</cell><cell>90.4</cell><cell>26.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>41ars in the present study, and in women aged 15-25 years in a previous study (NCT00689741 and NCT00120848)41Age ranges indicate the ages of women at the time of the first vaccination dose.</s></p></div></figDesc><table><row><cell>Antigen</cell><cell>Antibody levels</cell><cell>Model</cell><cell cols="4">Duration ensuring antibody levels above those induced by natural</cell></row><row><cell></cell><cell>induced by natural</cell><cell></cell><cell></cell><cell cols="3">infection in 95% participants (years)</cell></row><row><cell></cell><cell>infection (EU/mL)*</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Current study</cell><cell></cell><cell>Previous modelling</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>study**</cell></row><row><cell></cell><cell></cell><cell></cell><cell>15-25 years</cell><cell>26-45 years</cell><cell>46-55 years</cell><cell>15-25 years old***</cell></row><row><cell></cell><cell></cell><cell></cell><cell>old***</cell><cell>old***</cell><cell>old***</cell><cell></cell></row><row><cell>HPV-16</cell><cell>29.8</cell><cell>Modified power-law</cell><cell>Lifelong</cell><cell>Lifelong</cell><cell>Lifelong</cell><cell>Lifelong</cell></row><row><cell></cell><cell></cell><cell>Piecewise</cell><cell>40.08</cell><cell>16.9</cell><cell>12.1</cell><cell>26.7</cell></row><row><cell>HPV-18</cell><cell>22.6</cell><cell>Modified power-law</cell><cell>Lifelong</cell><cell>Lifelong</cell><cell>4.3 years</cell><cell>Lifelong</cell></row><row><cell></cell><cell></cell><cell>Piecewise</cell><cell>19.2</cell><cell>9.0</cell><cell>5.1</cell><cell>19.9</cell></row><row><cell cols="4">*Measured in a previous study in women who cleared natural infection. 30,31</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">**Women aged 15-25 years in a previous study (NCT00689741 and NCT00120848). 41</cell><cell></cell><cell></cell></row><row><cell>***</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>114 ª 2014 The Authors.</s><s>BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley &amp; Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley &amp; Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.HPV-16/18 vaccine persistence in women aged 15-55 years</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley &amp; Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="115">ª 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley &amp; Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.HPV-16/18 vaccine persistence in women aged 15-55 years</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors thank study participants and their families and the following principal investigators/co-investigators: G€ unter Cichon, Beate Leifels, and Dominik Pruski.</s><s>The authors also acknowledge the input and assistance of the following individuals at GlaxoSmithKline Vaccines: Ariane Meur ee (ELISA serology) and Laurence Luyten (ELISA on CVS) for laboratory support; Amulya Jayadev and Gr egory Catteau for statistical support; Lan Lin Cresens (</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure of interests</head><p><s>FT, DD, and PVS are employed by the GlaxoSmithKline (GSK) group of companies.</s><s>FT and DD own stock options in the GSK group of companies.</s><s>TFS, MS, and AMK have received support for travel to meetings for the study from the GSK group of companies.</s><s>JW has received travel, accommodation, and meeting reimbursements for participation in international scientific conferences, board membership, lectures, and consultancy on results from clinical trials.</s><s>TFS, AMK, and MS have received payment for lectures, including service on a speakers bureau, from the GSK group of companies.</s><s>TFS was paid for the development of educational presentations from the GSK group of companies.</s><s>AMK has received a research grant from the GSK group of companies.</s><s>TFS was paid for board membership and consultancy from the GSK group of companies.</s><s>Consulting fees or honoraria have been received by AMK for advisory board membership and presentations, by JW and his institution as payment for the clinical trial, and by MS.</s><s>AG and KS declare that they have no conflicts of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Contribution to authorship</head><p><s>All authors participated in the design, implementation, or analysis and interpretation of the study, and in the development of this article.</s><s>All authors had full access to the data and gave final approval before submission.</s><s>The corresponding author was responsible for the submission of the publication.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Details of ethics approval</head><p><s>All study procedures, the protocol, any amendment, and the informed consent were reviewed and approved by the following national independent ethics committees: Ethik-Kommission der Universit€ at W€ urzburg (</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the conduct of the study and the analysis.</s><s>GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of this article.</s></p><p><s>Published Online 11 September 2014.</s></p><p><s>The development of effective prophylactic vaccines against an infectious agent (human papillomavirus, HPV) that causes cervical cancer is a major milestone in preventive medicine.</s><s>In this article, Schwarz and co-workers demonstrated persistence for 6 years following immunisation with the Cervarix TM vaccine of high-titer antibodies to HPV-16/18 in the circulation and in cervicovaginal fluid in women aged 15-55 years.</s><s>Using statistical modelling it was also determined that antibody levels would persist for at least 20 years.</s><s>An exception was the possible loss of persistent immunity for women aged 46-55 years.</s></p><p><s>Several questions remain unanswered in relation to the HPV vaccine.</s><s>There is a need to assess whether the prevalent vaginal disorder, bacterial vaginosis (BV), decreases HPV antibody levels in vaccinated women to non-protective levels, and thereby increases susceptibility to HPV.</s><s>This would especially be a problem in resource-poor areas where the incidence of BV is usually elevated.</s><s>Continued analysis of the efficacy and consequences of HPV vaccination, especially in resource-poor areas, remains a priority.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure of interests</head><p><s>None.&amp;</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The causal relation between human papillomavirus and cervical cancer</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lorincz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="244" to="265" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Estimated cancer incidence, mortality and orevalence in 2012</title>
		<ptr target="http://globocan.iarc.fr/Pages/fact_sheets_population.aspx" />
	</analytic>
	<monogr>
		<title level="j">WHO. International Agency for Research on Cancer. GLOBOCAN</title>
		<imprint>
			<biblScope unit="volume">2012</biblScope>
			<date type="published" when="2014-01">January 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses</title>
		<author>
			<persName><forename type="first">V</forename><surname>Cogliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Straif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Grosse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Secretan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Ghissassi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">204</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Global cancer statistics</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pisani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="74" to="108" />
			<date type="published" when="2002">2002. 2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Human papillomavirus and cervical cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Castle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jeronimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wacholder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="890" to="907" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Human papillomavirus is a necessary cause of invasive cervical cancer worldwide</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Walboomers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Manos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="12" to="19" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zur Hausen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="690" to="698" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m">WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2010. Human Papillomavirus and Related Cancers. Summary Report Update</title>
				<imprint>
			<date type="published" when="2010-09-15">September 15, 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bruni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Castellsague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ferrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Sanjose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="1789" to="1799" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>De Sanjose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Castellsague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bruni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Munoz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="453" to="459" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The epidemiology of human papillomavirus infections</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Baseman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Koutsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Virol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S16" to="24" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Burchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Giuliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Sanjose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bruni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="K1" to="16" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Age-specific prevalence of infection with human papillomavirus in females: a global review</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Melendy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Rana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pimenta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Adolesc Health</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="S5" to="25" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The natural history of cervical HPV infection: unresolved issues</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Woodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Young</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="11" to="22" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Cervical cancer vaccination indications, efficacy, and side effects</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bayas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Costas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Munoz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S11" to="14" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl 2</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study</title>
		<author>
			<persName><forename type="first">S</forename><surname>De Sanjose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Quint</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alemany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Geraets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Klaustermeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lloveras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1048" to="1056" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Epidemiologic classification of human papillomavirus types associated with cervical cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Sanjose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Castellsague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope unit="page" from="518" to="527" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lindsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hoots</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Keys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Franceschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Winer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="621" to="632" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Castle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wheeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="1066" to="1071" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women</title>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="182" to="192" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Castle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hildesheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bratti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="page" from="1808" to="1816" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Aguado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Franceschi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Variations in the age-specific curves of human papillomavirus prevalence in women worldwide</title>
		<author>
			<persName><forename type="first">S</forename><surname>Franceschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Snijders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arslan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Anh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="2677" to="2684" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Human papillomavirus infection in adolescent and young women</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lawson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mo Med</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="42" to="46" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">HPV infections in adolescents</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Moscicki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Markers</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="229" to="234" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives</title>
		<author>
			<persName><forename type="first">X</forename><surname>Castellsague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kaufmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S15" to="23" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Descamps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Spiessens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Izurieta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Verstraeten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Breuer</surname></persName>
		</author>
		<idno>16/18</idno>
		<imprint>
			<biblScope unit="volume">of human papillomavirus</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials</title>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="332" to="340" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/ 18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="1975" to="1985" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="983" to="998" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spaczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wysocki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schulze</surname></persName>
		</author>
		<idno>HPV-16/18</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years</title>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="958" to="965" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women</title>
		<author>
			<persName><forename type="first">De</forename><surname>Carvalho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roteli-Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Naud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Borba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zahaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="6247" to="6255" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Franco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Ferris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schuind</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="1757" to="1765" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Harper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Franco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Moscicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Romanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Roteli-Martins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="1247" to="1255" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9</title>
		<author>
			<persName><forename type="first">P</forename><surname>Naud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Roteli-Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Carvalho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Borba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zahaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Presented at: International Papillomavirus Conference</title>
				<meeting><address><addrLine>Berlin, Germany</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2011">September 17-22, 2011</date>
		</imprint>
	</monogr>
	<note>4 years (Conference abstract</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Paavonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Naud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salmeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wheeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="2161" to="2170" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Paavonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Naud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salmeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wheeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Apter</surname></persName>
		</author>
		<idno>16/18</idno>
		<imprint>
			<biblScope unit="volume">of human papillomavirus</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="301" to="314" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Roteli-Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Naud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Borba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Carvalho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Zahaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin Immunother</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="390" to="397" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Efficacy, safety and immunogenicity of the HPV-16/ 18 AS04-adjuvanted vaccine in women over 25 years: 4-year interim follow-up of the double-blind, randomised VIVIANE study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Skinner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Szarewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Romanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Garland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lazcano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salmer On</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(14)60920-X</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Epub ahead of Print</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines</title>
		<author>
			<persName><forename type="first">T</forename><surname>Verstraeten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Descamps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zahaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Izurieta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="6630" to="6638" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)</title>
		<author>
			<persName><forename type="first">Agency</forename><surname>European Medicines</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Committee for Medicinal Products for Human Use (CHMP)</note>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title level="m" type="main">Immunogenicity and tolerability of an</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spaczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wysocki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perona</surname></persName>
		</author>
		<idno>HPV-16/18</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years</title>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="581" to="587" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Dessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Giannini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Bougelet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kemp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Poncelet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="425" to="434" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Van Herck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tibaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Descamps</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S1" to="6" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Persistence of immune response 5 years after administration of HPV-16/18 AS04-adjuvanted vaccine to women aged 15-55 years</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spaczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wysocki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schulze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Genital Infection and Neoplasia -2011 Interim Conference (AOGIN)</title>
				<meeting><address><addrLine>Bali, Indonesia</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2011">March 17-19 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/ adolescent girls and young women</title>
		<author>
			<persName><surname>Pet€ Aj€ A T</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Poder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Catteau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="2147" to="2157" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Aging and immune function: molecular mechanisms to interventions</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ponnappan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Ponnappan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antioxid Redox Signal</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1551" to="1585" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Leo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S1" to="10" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Suppl 1</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Viscidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hildesheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Castle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bratti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="324" to="327" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">In vivo mechanisms of vaccine-induced protection against HPV infection</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Kines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jagu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Roden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Lowy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Host Microbe</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="260" to="270" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections</title>
		<author>
			<persName><forename type="first">M</forename><surname>Safaeian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wacholder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gonzalez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="1653" to="1662" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kocken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Petaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Einstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Spaczynski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Louwers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1054" to="1061" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Prophylactic HPV vaccines: underlying mechanisms</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stanley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Lowy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Frazer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="106" to="113" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls</title>
		<author>
			<persName><forename type="first">E</forename><surname>Draper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Bissett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Howell-Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Soldan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e61825</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
